Loading
A phase 2 trial of PF-07248144, Fulvestrant, Letrozole in prostate cancer and non-small-cell lung cancer, run by Pfizer, now recruiting.
Study of PF-07248144 in Advanced or Metastatic Solid Tumors is a phase 2 interventional study registered as NCT04606446 by Pfizer, with 320 participants planned, started 2020-11-16 and due to reach its primary completion in 2029-07-13. Interventions recorded: PF-07248144, Fulvestrant, Letrozole, Palbociclib, PF-07220060. Conditions listed: Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Atirmociclib, Letrozole (and other aromatase inhibitors), Fulvestrant, Pfizer (incl. Seagen).
Shares Letrozole (and other aromatase inhibitors), Palbociclib, Fulvestrant, Pfizer (incl. Seagen).
Shares Atirmociclib, Vepdegestrant, UCSF Helen Diller Family Comprehensive Cancer Center, Pfizer (incl. Seagen).
Shares Atirmociclib, Palbociclib, UCSF Helen Diller Family Comprehensive Cancer Center, Pfizer (incl. Seagen).
Shares Palbociclib, Fulvestrant, UCSF Helen Diller Family Comprehensive Cancer Center, Pfizer (incl. Seagen).
Shares Atirmociclib, Fulvestrant, Pfizer (incl. Seagen).
Shares PF-07248144, Pfizer (incl. Seagen).
Shares Vepdegestrant, Palbociclib, Pfizer (incl. Seagen).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/